Targeted therapy: An evolving world of lung cancer

Respirology

Volumn 16, Issue 1, 2011, Pages 13-21

  Lam, Kwok Chi ^a   Mok, Tony S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti angiogenesis; Bevacizumab; Epidermal growth factor receptor; Gefitinib; Lung cancer

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; FIGITUMUMAB; GEFITINIB; GEMCITABINE; LAPATINIB; NAVELBINE; NERATINIB; PACLITAXEL; PEMETREXED; PF 299804; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; ANOREXIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; REVIEW; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79952260258     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01821.x     Document Type: Review

References (69)

1. Parkin DM, Bray FI, Devasa SS et al. Cancer burden in the year 2000: the global picture. Eur. J. Cancer 2001; 37: S4-66.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-909.
3. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 2002; 346: 92-8. (Pubitemid 34438899)
4. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 2000; 18: 2095-103. (Pubitemid 30324363)
5. Fossella FV, Devore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens: TAX 320 Non-small Cell Lung Cancer Study Group. J. Clin. Oncol. 2000; 18: 2354-62. (Pubitemid 30415821)
6. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004; 22: 1589-97. (Pubitemid 41079796)
7. Joriseen RN, Walker F, Pouliot N et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 2003; 284: 31-53. (Pubitemid 36331965)
8. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 2129-39. (Pubitemid 38637993)
9. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500. (Pubitemid 38720929)
10. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 2004; 101: 13306-11. (Pubitemid 39209661)
11. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005; 23: 1011-27. (Pubitemid 46202320)
12. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J. Clin. Oncol. 2003; 21: 2237-2.
13. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003; 290: 2149-58. (Pubitemid 37432975)
14. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study [Iressa Survival Evaluation in Lung Cancer]. Lancet 2005; 366: 1527-37. (Pubitemid 41540110)
15. Chang A, Parikh P, Thongprasert S et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL Study. J. Thorac. Oncol. 2006; 1: 847-55. (Pubitemid 47181391)
16. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small cell lung cancer. N. Engl. J. Med. 2005; 353: 123-32. (Pubitemid 41058344)
17. Cohen MH, Johnson JR, Chen YF et al. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005; 10: 461-6. (Pubitemid 41266326)
18. Mauryama R, Nishiwaki Y, Tamura T et al. Phase III Study, V-15- 32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small cell lung cancer. J. Clin. Oncol. 2008; 26: 4244-52.
19. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008; 372: 1809-18.
20. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial - INTACT 2. J. Clin. Oncol. 2004; 22: 785-94. (Pubitemid 41103589)
21. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J. Clin. Oncol. 2005; 23: 5892-9.
22. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III Trial- INTACT 1. J. Clin. Oncol. 2004; 22: 777-84. (Pubitemid 41103588)
23. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 2007; 25: 1545-52. (Pubitemid 46733081)
24. Gumerlock PH, Pryde BJ, Kimura T et al. Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma. Proc. Am. Soc. Clin. Oncol. 2003; 22: Abstr 2661.
25. Piperdi B, Ling YH, Kroog G et al. Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro. J. Clin. Oncol. 2004; 22 (14S): 7028.
26. Mahaffey CM, Davies AM, Lara PN et al. Schedule-dependent apoptosis in K-ras mutant non-small cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin. Lung Cancer 2007; 8: 548-53. (Pubitemid 350292228)
27. Li TH, Ling YH, Goldman D et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell cancer cells. Clin. Cancer Res. 2007; 13 (11): 3413-22.
28. Davies AM, Hesketh PJ, Beckett L et al. Pharmacodynamic separation of erlotinib and docetaxel in advanced non-small cell lung cancer: overcoming hypothesized antagonism. Proc. Am. Soc. Clin. Oncol. 2007; 25: 18S; Abstr 7618.
29. Mok SK, Wu YL, Yu CJ et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small cell lung cancer. J. Clin. Oncol. 2009; 27: 5080-7.
30. Butts CA, Bodkin D, Middleman EL et al. Randomization phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 2008; 25: 5777-84.
31. Rosell R, Robinet G, Szczesna A. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/ vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small cell lung cancer. Ann. Oncol. 2008; 19: 362-9. (Pubitemid 351201721)
32. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small cell lung cancer: results of the randomized multicenter phase III trial BMS099. J. Clin. Oncol. 2010; 28: 911-17.
33. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009; 373: 1525-31.
34. Mok SK, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-57.
35. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 2008; 26: 2442-9.
36. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 2009; 361: 958-67.
37. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicenter, randomized placebo-controlled phase III study. Lancet Oncol. 2010; 11: 521-9.
38. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 2004; 22: 2184-91. (Pubitemid 41095154)
39. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for Non-small cell lung cancer. N. Engl. J. Med. 2006; 355: 2542-50. (Pubitemid 44917502)
40. Reck M, Pawel JV, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small cell lung cancer. J. Clin. Oncol. 2009; 27: 1227-34.
41. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 2009; 27: 740-5.
42. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009; 27: 4733-40.
43. Socinski MA, Langer CJ, Huang JE et al. Safety of bevacizumab in patients with non-small cell lung cancer and brain metastasis. J. Clin. Oncol. 2009; 27: 5255-61.
44. Blumenschein GR, Gatzemeier U, Fossella F et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory advanced non-small cell lung cancer. J. Clin. Oncol. 2009; 27: 4274-80.
45. Hanna NH, Pawel JV, Reck M et al. Carboplatin/paclitaxel with/ without sorafenib in chemonaive patients with stage IIIB-IV non-small cell lung cancer: interim analysis results from a randomized phase III trial (ESCAPE). J. Thorac. Oncol. 2008; 3: S268.
46. Socinski MA, Novello S, Brahmer JR et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small cell lung cancer. J. Clin. Oncol. 2008; 26: 650-6. (Pubitemid 351264362)
47. Novello S, Scagliotti GV, Rosell R et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br. J. Cancer 2009; 101: 1543-8.
48. Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 1997; 151 (6): 1523-30. (Pubitemid 27527914)
49. Hirata A, Ogawa S, Kometani T et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 2002; 62 (9): 2554-60. (Pubitemid 34462734)
50. Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 2003; 9 (4): 1546-56. (Pubitemid 36418413)
51. Herbst RS, Mininberg E, Henderson T et al. Phase I/II trial evaluating blockade of tumor blood supply and tumor cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer. Eur. J. Cancer 2003; 1: S293.
52. Guy SP, Asthon SE, Hughes G et al. Gefitinib (Iressa, ZD1839) enhances the activity of the novel vascular-targeting agent ZD6126 in human colorectal and non-small cell lung cancer xenograft models. Clin. Cancer Res. 2003; 9: B13.
53. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/ epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J. Clin. Oncol. 2005; 25: 2544-55.
54. Herbst RS, O'Neil VJ, Fehrenbacher L et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J. Clin. Oncol. 2007; 25: 4743-50. (Pubitemid 350086476)
55. Hainsworth J, Herbst R. A phase III, multicenter, placebo, controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer. J. Thorac. Oncol. 2008; 3 (11 Suppl. 4): S302.
56. Natale RB, Thongprasert S, Greco FA et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase II trial (ZEST). J. Clin. Oncol. 2009; 27: 15s; Abstr 8009.
57. De Boer R, Arrieta O, Gorrfried M et al. Vandetanib plus pemetrexed versus pemetrexed as seconde-line therapy in patients with advanced non-small cell lung cancer: a randomized, doubleblind phase III trial (ZEAL). J. Clin. Oncol. 2009; 27: 15s; Abstr 8010.
58. Herbst RS, Sun Y, Korfee S et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer: a randomized, double-blind phase III trial (ZODIAC). J. Clin. Oncol. 2009; 27: 18s; Abstr CRA 8003.
59. Engelman JA, Janne P. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 2008; 14 (10): 2895-9.
60. Chakravarti A, Loeffler JS, Dyson NJ et al. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide-3-kinase signaling. Cancer Res. 2002; 62: 200-7. (Pubitemid 34074005)
61. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27: 4702-11.
62. Yang C, Hirsh V, Cadranel J et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). J. Clin. Oncol. 2009; 27: 15s; Abstr 8062.
63. Shih J, Yang C, Su W et al. A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor, in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2). J. Clin. Oncol. 2009; 27: 15s; Abstr 8013.
64. Wong HH, Fracasso PM, Bukowski RM et al. A phase I study of neratinib (HKI-272), an irreversible Pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin. Cancer Res. 2009; 15: 2552-8.
65. Engelman JA, Zejnullahu K, Gale CM et al. PF00299804, an irreversible Pan-ErbB inhibitor, is effective in lung cancer models with EGFR and ErbB2 mutations that are resistant to gefitinib. Cancer Res. 2007; 67 (24): 11924-32.
66. Janne PA, Reckamp K, Koczywas M et al. Efficacy and safety of PF-00299804 (PF299) in patients with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib: a two-arm phase II trial. J. Clin. Oncol. 2009; 27: 15s; Abstr 8063.
67. Karp DD, Paz-Ares LG, Novello S et al. Phase II study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in combination with Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non- Small Cell Lung Cancer. J Clin. Oncol. 2009; 27: 2516-22.
68. Kim HP, Han SW, Kim SH et al. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol. Cancer Ther. 2008; 7 (3): 607-15.
69. Regales L, Gong Y, Shen R et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J. Clin. Invest. 2009; 119 (10): 3000-10.